Nachrichten zur Axsome Therapeutics Inc. Aktie

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up…

Form 8-K Axsome Therapeutics, For: Feb 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Thinking about trading options or stock in AutoNation, DoorDash, Axsome Therapeutics, NVIDIA, or Microsoft?

NEW YORK, Feb. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AN, DASH, AXSM, NVDA, and MSFT. Click…

Axsome slips as Teva seeks generic for depression therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Axsome Therapeutics, For: Feb 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27

Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET Axsome to host conference…

Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout

Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline…

Better Buy: Moderna vs Axsome

Revenue prospects look promising for both of these biotech companies....…

After Jumping 100%, Is Axsome a Buy Before 2023?

Axsomes revenue story is just getting started....…

Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

Axsome Therapeutics Stock: Bear vs. Bull

2023 will almost certainly see Axsomes top line explode higher....…

Axsome Therapeutics Shares Hit 52-Week High, Propelled by Alzheimers Study >AXSM

Axsome Therapeutics Shares Hit 52-Week High, Propelled by Alzheimer's Study >AXSM...…

Axsome Therapeutics Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Axsome Therapeutics (NASDAQ:AXSM). And retail traders should…

Thinking about trading options or stock in Axsome Therapeutics, Sarepta Therapeutics, Las Vegas Sands, Apple, or Microsoft?

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SRPT, LVS, AAPL, and MSFT. Click…

Axsome says candidate for Alzheimer’s agitation met main goal in late-stage trial

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AKTIONÄR-Hot-Stock Axsome mit Alzheimer-Top-News: Aktie gewinnt 20 Prozent

Die Aktie von Axsome Therapeutics startet zu Wochenbeginn gleich mit einem kräftigen Kurssprung. Das Papier gewinnt auf der Handelsplattform Tradegate…

Form 8-K Axsome Therapeutics, For: Nov 28

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Shares Rally Premarket on Alzheimers Agitation Study Success >AXSM

Axsome Shares Rally Premarket on Alzheimer's Agitation Study Success >AXSM...…

Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

Is Axsome Therapeutics Stock a Buy Now?

The company seems to be coming into its own....…

Axsome gains as Cantor favors rollout of new portfolio additions

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Axsome Therapeutics Stock Is Bolting Higher Today

The biotechs promising Q3 earnings report has investors excited about the future....…

Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss

Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from…

Why Axsome Therapeutics Stock Slipped Today

Investors traded out of the company following the latest earnings release, but only to a modest degree....…

Form 10-Q Axsome Therapeutics, For: Sep 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of 6.36% and 1.56%, respectively, for the quarter ended September 2022. Do the…

Axsome Therapeutics GAAP EPS of -$1.07 beats by $0.02, revenue of $16.8M misses by $0.26M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Axsome Therapeutics, For: Nov 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Axsome Therapeutics Q3 2022 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is a Surprise Coming for Axsome (AXSM) This Earnings Season?

Axsome (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....…

2 Top Biotech Stocks Defying the Bear Market

While the S&P 500 is down about 20% year to date, biotech stocks Vertex Pharmaceuticals and Axsome Therapeutics have been…

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022

Axsome to host conference call and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time...…

Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared…

dpa-AFX ProFeed